4 ms·
sounds like once again, YC is choosing to dilute the quality of their offering in order to capture more of the VC pie. I suppose this inevitable for any entity
by forgotmysn 6y ago
sounds like once again, YC is choosing to dilute the quality of their offering in order to capture more of the VC pie. I suppose this inevitable for any entity in a competitive space, but it's still disappointing to see.
nevertheless, everytime YC does this, it makes every other accelerator program out there more valuable comparatively.
- ramraj07 6y agoCrazy to think it’s dilution now that more atypical companies are funded? I also have genuine concerns with the quality of evaluation in bio fields but when we make criticism that can also be explained by bias then we critics have a burden to clarify if we gave enough thought to that possibility that we are just offended by the new.
- forgotmysn 6y agoi dont think you need to worry about bias in that case. there are definitely more competitive accelerators out there for bio and biotech companies